-
Signature
-
/s/ Kamran Alam, Attorney-in-Fact
-
Issuer symbol
-
TSHA
-
Transactions as of
-
10 Sep 2025
-
Net transactions value
-
-$617,240
-
Form type
-
4
-
Filing time
-
12 Sep 2025, 16:15:25 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Nagendran Sukumar |
President and Head of R&D, Director |
C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS |
/s/ Kamran Alam, Attorney-in-Fact |
12 Sep 2025 |
0001665124 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
TSHA |
Common Stock |
Options Exercise |
$28,760 |
+41,150 |
+3.5% |
$0.6989 |
1,206,439 |
10 Sep 2025 |
Direct |
|
| transaction |
TSHA |
Common Stock |
Sale |
$646,000 |
-200,000 |
-17% |
$3.23 |
1,006,439 |
10 Sep 2025 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
TSHA |
Employee Stock Option (right to buy) |
Options Exercise |
$0 |
-41,150 |
-12% |
$0.000000 |
292,855 |
10 Sep 2025 |
Common Stock |
41,150 |
$0.6989 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: